Lawsuit filed for Investors in shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS)

An investor, who purchased shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS), filed a lawsuit over alleged violations of Federal Securities Laws by Aclaris Therapeutics, Inc. .

Investors who purchased shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) have certain options and for certain investors are short and strict deadlines running. Deadline: September 30, 2019. NASDAQ: ACRS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Wayne, PA based Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. Aclaris Therapeutics, Inc. reported that its annual Total Revenue rose from $1.68 million in 2017 to $10.09 million in 2018. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy. Specifically, “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders . . . in the case of exposure to the eye and severe skin reactions including scarring.”

The plaintiff claims that between May 8, 2018 and June 20, 2019, the Defendants failed to disclose to investors that the Company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales, that, as a result, the Company was reasonably likely to face regulatory scrutiny, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.